Skip to main content
. Author manuscript; available in PMC: 2021 Jul 15.
Published in final edited form as: Clin Cancer Res. 2020 Nov 16;27(2):380–382. doi: 10.1158/1078-0432.CCR-20-3877

Figure.

Figure.

Putative mechanisms of sensitivity or resistance to PD-1 inhibitor therapy or PARP inhibitor therapy among CDK12-deficient prostate cancer patients. Understanding the potential genomic, transcriptomic and immune microenvironment differences in CDK12-altered prostate cancers may help to guide treatment decisions for this subset of patients.